Through an adapted ELISA test, which allows for the detection, characterisation andquantification of exosomes, it has been demonstrated that tumour patients have significantlyincreased plasmatic levels of exosomes expressing CAV1 compared with the plasma of healthydonors34 and even CD63.35 This evidence concerns the gene CD63 and neoplasm.